Epidemiology and Potential Pathomechanisms of Cardiovascular Comorbidities in Psoriasis: A Report from the GRAPPA 2010 Annual Meeting

WOLF-HENNING BOEHNCKE

ABSTRACT. There is increasing awareness that psoriasis is more than “skin deep.” Several recent reviews focused on biomarkers have indicated the systemic dimension of psoriasis and the comorbidity that psoriasis shares with other chronic inflammatory diseases. Of emerging significance is the relationship to cardiovascular disease, which contributes substantially to patients’ increased mortality. This article examines currently available evidence favoring the concept of a causal link between psoriasis and cardiovascular disease, and summarizes a report represented at the 2010 Annual Meeting of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis). (J Rheumatol 2012;39:441–4; doi:3899/jrheum.111245)

Key Indexing Terms:
ADIPOKINE                    ATHEROSCLEROSIS                    ENDOTHELIAL CELL DYSFUNCTION
INSULIN RESISTANCE                                                                 PSORIASIS

This paper includes ideas presented previously by Prof. Dr. Boehncke in another publication: Boehncke WH, et al. The ‘psoriatic march’: A concept of how severe psoriasis may drive cardiovascular morbidity. Exp Dermatol 2011;20:303-7.

Epidemiology and the Concept of the “Psoriatic March”
There is increasing awareness that psoriasis is more than skin deep and that it has important systemic manifestations that are shared with other chronic inflammatory diseases, such as rheumatoid arthritis. Of emerging significance is the relationship between cardiovascular disease and severe psoriasis, which may explain the increased rate of mortality in patients with psoriasis. The diagnosis “severe psoriasis” in this context refers to all patients who at any point in time received either systemic therapy or phototherapy or were treated on an inpatient basis. As many as one-third of all patients with psoriasis meet these criteria.

Cardiovascular comorbidity is well known to rheumatologists, because it occurs in patients with rheumatoid arthritis or psoriatic arthritis (PsA). When trying to dissect the relative contribution of PsA and coexisting psoriasis, Gladman, et al determined that high scores on the Psoriasis Area and Severity Index (which measures activity and severity of psoriasis of the skin) are major predictors for cardiovascular disease.

Associations do not per se establish a causal relationship between disorders, but the concept of psoriasis as an independent cardiovascular risk factor is gaining support. In Sweden, an increased cardiovascular mortality was observed among psoriasis inpatients (probably with more severe disease), but not in outpatients. Additionally, a recent population-based study identified severe psoriasis as an independent risk factor for myocardial infarction, and a case-control study showed substantially elevated levels of coronary artery calcification as an indicator for coronary artery disease among inpatients with psoriasis compared to controls matched for all major known cardiovascular risk factors. Other studies found the adjusted odds ratio of developing myocardial infarction for patients with psoriasis to range from 1.6 to 1.8.

One must acknowledge that patients with severe psoriasis appear to have an excess of “traditional” risk factors for the development of cardiovascular disease. A recent review outlined a scenario on how psoriasis unfolds from gene to clinic, with comorbidity “likely...result[ing] from chronic inflammation.” Another study describes the cascade of events leading to type 2 diabetes mellitus, given initial findings on insulin resistance among patients with psoriasis (the “psoriatic march,” Figure 1). The present article examines the currently available evidence to support causal- ity of this cascade in psoriasis.

Severe Psoriasis Is Associated with Elevated Biomarkers Indicating a State of Systemic Inflammation
Several biomarkers indicating systemic inflammation have been shown to be elevated in psoriasis patients. These include adipokines, i.e., cytokines produced by adipo-
Insulin may also activate the proatherogenic mitogen-activated protein kinase pathway in endothelial cells. Leukocytes, smooth muscle growth, impaired coagulation, vascular inflammation, atherosclerosis, and thrombosis are all consequences of this pathway mediating insulin’s metabolic effects. However, release of vasodilating and vasoconstricting factors when this balance is changed predisposes the endothelium toward an atherogenic milieu, which may cause rolling of leukocytes.

Insulin Resistance Triggers Endothelial Cell Dysfunction

Endothelial cell dysfunction refers to an imbalance in the release of vasodilating and vasoconstricting factors. When this balance is changed, it predisposes the endothelium toward an atherogenic milieu, which may cause rolling of leukocytes, smooth muscle growth, impaired coagulation, vascular inflammation, atherosclerosis, and thrombosis. In atherosclerotic coronary arteries, vasodilation is impaired and a paradoxical constriction may occur, suggestive of endothelial cell dysfunction. Several lines of evidence provide links between insulin resistance and endothelial cell dysfunction, particularly the insulin receptor substrate-1 (IRS-1). IRS-1 is one of the key proteins downstream of the insulin receptor for signaling metabolic effects, such as uptake in fat cells and NO production in endothelial cells. When cellular IRS-1 identifies individuals who are markedly insulin-resistant and exhibit evidence of early atherosclerosis. Moreover, low IRS-1 expression may be a marker for not only insulin resistance but also arterial stiffness. These data imply that shared stressors, such as hyperglycemia, cause oxidative stress and downregulation of IRS-1 in fat cells and endothelial cells, leading to insulin resistance and endothelial cell dysfunction.

Systemic Inflammation Induces Insulin Resistance

Insulin resistance, i.e., reduced uptake of glucose by metabolically active cells upon exposure to insulin, is reflected at the clinical level by the homeostasis model assessment of insulin resistance. A more sensitive test for insulin resistance is the oral glucose tolerance test. Using these methods, 2 cross-sectional studies showed that psoriasis patients exhibit insulin resistance at clinical levels. The notion of insulin being a vasoactive hormone is of particular relevance: intravenously administered insulin enhances blood flow and vasodilation in a nitric oxide (NO)-dependent manner. This pathway involves activation of phosphoinositide 3-kinase and leads to phosphorylation of endothelial NO synthase; it is therefore related to the pathway mediating insulin’s metabolic effects. However, insulin may also activate the proatherogenic mitogen-activated protein kinase pathway in endothelial cells.

Endothelial Cell Dysfunction Drives Atherosclerosis

As stated above, a change in the balance of vasodilating and vasoconstricting factors predisposes the endothelium toward atherosclerosis, which is now regarded as an inflammatory disease. Early events comprise adhesion-mediated leukocyte extravasation, which is facilitated by activated platelets and followed by infiltrating macrophages, releasing cytokines and enzymes such as matrix metalloproteinases, thus degrading the connective tissue matrix. This step is followed by the formation of a more advanced fibrous lesion with accumulating lipid-rich necrotic debris and smooth muscle cells. This fibrous-capped plaque then develops into an advanced and very complex lesion. Continuing inflammation may alter the fibrous cap to create an unstable plaque, rupture of which would cause thromboembolic complications, such as myocardial infarction or stroke.

Toward a Concept for Comprehensive Monitoring of Patients with Severe Psoriasis

It is still unclear how the relationships discussed here are really causal in nature. However, the epidemiological data reveal that patients with severe psoriasis often have comorbidity, most importantly premature cardiovascular disease. Management of patients with severe psoriasis therefore requires more than the assessment and treatment of skin symptoms alone.

Recently, the National Psoriasis Foundation published screening recommendations for psoriasis patients. The cardiovascular comorbidity recommendations are derived from the American Heart Association, but they do not include psoriasis itself as an independent risk factor for cardiovascular diseases. However, another publication does define target ranges for patients with psoriasis, with specific characteristics depending on the number of additional cardiovascular risk factors (Table 1).
In an example of the benefits of more comprehensive psoriasis treatment, obese patients with moderate to severe psoriasis had a better response to low-dose cyclosporine in a controlled clinical trial if a calorie-reduced diet was included in their treatment regimen. Whether the psoriatic march can be stopped through early continuous systemic therapy has been addressed indirectly in two retrospective analyses: one shows that long-term continuous methotrexate treatment reduces cardiovascular morbidity among psoriasis patients; the other documents reduction of C-reactive protein as a biomarker for cardiovascular risk in a registrational study with the tumor necrosis factor-α-blocking biologic etanercept. Several prospective studies have directly addressed this question and demonstrated that successful continuous systemic antipsoriatic therapy ameliorates biomarkers for cardiovascular risk, including cytokines, adipokines, and endothelial cell dysfunction.

**Conclusion**

The concept of psoriasis being causally related to cardiovascular comorbidity, i.e., organ-specific inflammation driving atherosclerosis, is supported by an increasing number of studies. More efforts at the level of both clinical and basic research are needed to develop a foundation upon which we can base a comprehensive approach to the management of psoriasis. This will remain an important topic for ambitious scientists in cutaneous biology and related fields for years to come.

**REFERENCES**

8. Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT.


